Published in final edited form as:

J Med Chem. 2012 June 14; 55(11): 5174–5187. doi:10.1021/jm300176j.

(Z)-1-Aryl-3-arylamino-2-propen-1-ones, Highly Active Stimulators of Tubulin Polymerization: Synthesis, Structure Activity Relationship (SAR), Tubulin Polymerization and Cell Growth Inhibition Studies

M.V. Ramana Reddy^{1,*}, Balaiah Akula^{2,#}, Stephen C Cosenza^{1,#}, Clement M Lee¹, Muralidhar R Mallireddigari², Venkat R Pallela², DRC Venkata Subbaiah¹, Andrew Udofa¹, and E. Premkumar Reddy^{1,*}

¹Department of Oncological Sciences, Mount Sinai School of Medicine, Icahn Medical Institute, 1425 Madison Ave., New York, NY 10029-6514

²Department of Medicinal Chemistry, Onconova Therapeutics Inc., 375 Pheasant Run, Newtown, PA 18940

Abstract

Tubulin, the major structural component of microtubules, is a target for the development of anticancer agents. A series of (Z)-1-Aryl-3-arylamino-2-propen-1-one (**10**) were synthesized and evaluated for anti-proliferative activity in cell based assay. The most active compound (Z)-1-(2-bromo-3,4,5-trimethoxyphenyl)-3-(3-hydroxy-4-methoxyphenylamino)-prop-2-en-1-one (**10ae**) was tested in 20 tumor cell lines including multidrug resistant phenotype and was found to induce apoptosis in all these cell lines with similar GI₅₀ values. Flow cytometry studies showed that **10ae** arrested the cells in G2/M phase of cell cycle. In addition to G2/M block, these compounds caused microtubule stabilization like paclitaxel and induced apoptosis via activation of the caspase family. The observations made in this investigation demonstrate that (Z)-1-Aryl-3- arylamino-2-propen-1-one (**10**) represents a new class of microtubule – stabilizing agents.

Introduction

Tubulin containing structures, such as microtubules are important for the formation of the mitotic spindle during the process of mitosis. They play a critical role in cell growth, division and cytoskeletal organization of normal and tumor cells as well as being implicated in motility, shape and intracellular transport.¹ Microtubules are hollow tubes of α - and β -tubulin heterodimers that polymerize parallel to a cylindrical axis. Tubulin binding molecules interfere with the dynamic instability of microtubules and thereby disrupt microtubules inducing cell cycle arrest in the M-phase, forming abnormal mitotic spindles resulting in the apoptotic cell death.² A number of natural compounds (see chart 1) such as paclitaxel (**A**), epothilone (**B**), vinblastine (**C**), combretastatin A-4 (CA4) (**D**), dolastatin 10 (**G**), and colchicine (**H**), attack microtubules by interfering with the dynamics of tubulin polymerization and depolymerization, resulting mitotic arrest.³ However, many clinically useful chemotherapy drugs face substantial limitations, such as drug resistance, high systemic toxicity, complex syntheses, and isolation procedures. This has encouraged

*Corresponding Author: For M.V.R.R.: Phone, (212) 659-6875; Fax, (215) 893-6989, r.reddy@mssm.edu. For E.P.R.: Phone, (212) 659-5571; ep.reddy@mssm.edu.

#Author Contributions

These authors contributed equally.

scientists to develop new antimitotic agents. Recent studies have reported compounds targeting the colchicine-binding domain of β -tubulins that can act as vascular disrupting agents, rapidly depolymerizing microtubules of newly formed vasculature to block the blood supply to tumors,⁴ while leaving blood supply to healthy cells intact. These compounds include drug candidates Combretastatin A-4P (CA4P) (**E**), Oxi4503, R, R₁ = OPO₃Na₂ (**F**), ZD6126 (**I**) which are shown in chart 1.

The encouraging antivasular activity of compound **E** has stimulated significant interest in exploring new antitubulin agents. A variety of synthetic small molecules have been reported as inhibitors of polymerization, which compete with the colchicine-binding site of tubulin.⁵ Structurally, they involve various heteroaromatic cores, for instance including the benzothiophene,⁶ benzofuran,⁷ imidazole,⁸ thiazole,⁹ and oxadiazoline,¹⁰ moieties. A number of indole-based compounds, for example 2-arylindoles,¹¹ 3-arylindoles,¹² 3-aryl-2-phenylindoles,⁷ 3-arylthioindoles-2-carboxylate,¹³ and indolyl-3-glyoxamides¹⁴ have shown strong anti-proliferative and tubulin depolymerizing activity.

Compounds like paclitaxel promote tubulin polymerization into microtubules and block microtubule dynamics, leading to abnormal mitosis and subsequent apoptosis.^{15,16} Paclitaxel was the first microtubule-stabilizing agents (MSA) discovered.¹⁷ It promotes the *in vitro* polymerization of tubulin in the presence of guanosine triphosphate (GTP), which is normally required for microtubules assembly, and in cells, paclitaxel induces microtubule stabilization leading to the formation of characteristic microtubule bundles.¹⁸

Three non-taxoid compounds have also been shown to stabilize microtubules. The macrolides Epothilone A and Epothilone B (**B**) from the bacterium *Sorangium cellulosum*,¹⁹ and Discodermolide (**J**) from the marine sponge *Discodermia dissolute*,²⁰ share with Paclitaxel the ability to arrest cells in mitosis, cause formation of bundles of intracellular microtubules in nonmitotic cells, and induces the formation of hyperstable tubulin polymers.

A large number of small molecules have been described in the literature which inhibit tubulin polymerization *in vitro* and *in vivo* resulting in the arrest of the cells in mitosis, ultimately leading to apoptosis. So far only two reports have described small synthetic molecules that stimulate tubulin polymerization and microtubule stabilization.^{21,22} In this paper, we describe the synthesis, structure activity relationship (SAR) and mode of action of a new series of (*Z*)-1-Aryl-3-arylamino-2-propen-1-one (**10**) that stimulate tubulin polymerization and stabilizes microtubules..

Chemistry

The synthesis of target compounds (*Z*)-1-Aryl-3-arylamino-2-propen-1-one (**10**) is illustrated in Scheme 1. Arylaldehydes **1**, **2**, **3**, **6** were treated with ethynylmagnesium bromide in dry tetrahydrofuran (THF) at 0 °C to room temperature, produces 1-aryl-2-propyn-1-ol (**7**). Oxidation of **7** with 2-iodoxybenzoic acid (IBX) in the presence of dimethyl sulfoxide (DMSO) gave 1-aryl-2-propyn-1-one (**8**). Condensation of **8** with aryl amines (**9**) in ethanol at room temperature resulted in the formation of (*Z*)-1-aryl-3-arylamino-2-propen-1-one (**10**) in good yields.

Some of the substituted arylaldehydes (**2**, **3**, **6**), which are not commercially available were synthesized as shown in the schemes 2, 3 and 4. Chlorination of 3,4,5-trimethoxybenzaldehyde (**1c**) with sulfuryl chloride (SO₂Cl₂) in the presence of dichloromethane (CH₂Cl₂), afforded 2-chloro-3,4,5-trimethoxybenzaldehyde, **2** (Scheme 2). Similarly the corresponding bromo compound **3** was obtained according to methods reported in literature.²³ Bromination of 3,4,5-trimethoxybenzaldehyde (**1c**), with N-

Bromosuccinimide (NBS) in chloroform at reflux temperature for 3 h, afforded 2-bromo-3,4,5-trimethoxybenzaldehyde, **3** (scheme 3). Whereas, the 2-nitro-3,4,5-trimethoxybenzaldehyde, **6** resulted by the oxidation of (3,4,5-trimethoxy-2-nitrophenyl)methanol (**5**) with manganese dioxide (MnO_2) in the presence of chloroform (CHCl_3) at room temperature for 48 h. **5**, which in turn was obtained by reduction of methyl 3,4,5-trimethoxy-2-nitrobenzoate (**4**) with diisobutylaluminum hydride (DIBALH) in the presence of toluene at -50°C (scheme 4).

Structure-Activity Relationships (SAR)

After the synthesis of these compounds, their *in vitro* cytotoxicity was assessed using two different human tumor cell lines derived from human prostate (DU145) and leukemic (K562) cancers. The results of the study are presented in Table 1. These studies reveal that the cytotoxicity of the 1-aryl-3-arylamino-2-propen-1-ones (**10**) is totally dependent on the nature and position of the substituents present on the two aromatic rings. For the purpose of structure activity relationship, we have selected few compounds from a library of enaminones synthesized in our laboratory. The cytotoxicity data (Table 1 and data not shown) clearly shows that the molecules are inactive when both aromatic rings are mono substituted (**10a**). A moderate cytotoxicity was observed when benzoyl aromatic ring was tri substituted at 3rd, 4th and 5th positions with methoxy groups and anilino ring with a methoxy at 2nd position (**10k**). A fivefold increase in the activity was observed in **10k** when the 2-methoxy group on the anilino ring was relocated to 4th position (**10l**). When the pattern of substitution is reversed by keeping 3,4,5-trimethoxy groups on anilino ring and 4-methoxy group on the benzoyl ring (**10b**), the tumor cellular toxicity is reduced by more than 100 folds. These results show that the molecules with three methoxy groups on the benzoyl ring are more cytotoxic towards tumor cells than the compounds with three methoxy groups on the anilino ring. Once the benzoyl ring was identified as a correct moiety for tri substitution then we looked at the position of the methoxy groups on the ring in modulating the cytotoxicity of the molecule. To analyze the role of the position of the methoxy groups, we have made a number of compounds with 2,4,6-trimethoxy substitutions on the benzoyl ring (**10c**, **10d**, **10e**, **10f**, **10g** and **10h**). All the compounds with 2,4,6-trimethoxy benzoyl substituted lost the cytotoxicity effect on the tumor cells compared to the corresponding 3,4,5-trisubstituted benzoyl compounds. It clearly shows that **10l**, **10m** and **10o** which are 3,4,5-trimethoxy benzoyl are 50 fold more active than **10c** and **10e** which are 2,4,6-trimethoxy benzoyl enaminones. This confirms that the benzoyl ring of the enaminones presented in Table 1 require three methoxy groups at 3rd, 4th and 5th position to attain maximum cytotoxicity towards cancer cells. To analyze the effect of additional substituents on the aniline aromatic ring, we have synthesized a number of analogues containing 3-hydroxy-4-methoxy (**10p**), 3-amino-4-methoxy (**10q**), 3-fluoro-4-methoxy (**10r**), 3-chloro-4-methoxy (**10s**) and 2-chloro-5-hydroxy (**10t**) groups; the cytotoxicity analyses of these analogues showed that the compounds with hydroxy and amino substituents at third position (**10p**, **10q**) exhibited the best activity in the series compared to the halo substituents (**10r**, **10s**, and **10t**). These compounds **10p** and **10q** are 5 fold more active than **10l**. In an attempt to further enhance the activity of the molecule, we have replaced aryl anilines with heteroaryl anilines. The replacement of heteroaryl anilines did not improve the cytotoxicity of the molecules (**10w**, **10x**, **10y**, **10z**, **10aa** and **10ab**). After assigning 3rd, 4th and 5th positions to methoxy groups on benzoyl ring for optimum activity, we looked for the effect of a substituent at the *ortho* position of the benzoyl ring. It is clear from the cytotoxicity data of **10ac**, **10ad**, **10ae**, **10af**, **10ag** and **10ah**, the inclusion of a halo or a nitro group at the *ortho*-position moderately improved the activity of the molecules compared to the corresponding *ortho*-unsubstituted compounds. The SAR analysis of these compounds also shows that replacement of a methoxy (**10k** and **10l**), hydroxy (**10i** and **10j**) or chloro (**10m**)

or trifluoro (**10o**) atoms or groups in these compounds with trimethoxy groups at 3,4,5 (**10v**) or 2,4,6 (**10u**) positions of anilino ring lead to the total loss of activity.

Biological Results and Discussions

In vitro anti-tumor effects of **10ae** compound

We next tested the activity of the most active compound (**10ae**) listed in Table 1 against different human tumor cell lines and surprisingly, they were found to induce apoptosis of all of these cell lines with similar GI₅₀ values (*selected* data shown in Table 2). The wide range of cell killing across multiple tumor types suggests that this compound is inducing tumor cell killing by inhibiting an intrinsically important process of tumor cell division.

10ae compound is also active against drug resistant tumor cell line

Development of resistance to classical chemotherapeutic agents is widely observed in patients who have not responded or have relapsed after first round of therapy and is the primary cause of treatment failure. Many microtubulin poisons such as paclitaxel, vincristine, and vinblastine are substrates for the multidrug resistant family members. To further investigate the activity of these compounds against MDR positive tumor types, we determined the IC₅₀ value of **10ae** using a classical MDR positive cell line. The results shown in Table 2 show a 96 h dose response of the uterine sarcoma cell line MES-SA and the multidrug resistant sub-line MES-SA/DX5²⁴ treated with **10ae**. This cell line has been shown to express high levels of P-glycoprotein and is resistant to a number of drugs including doxorubicin, paclitaxel, vincristine, vinblastine, etoposide, mitoxantrone, dactinomycin, and daunorubicin. The activity of our compound was then compared to the activity of paclitaxel (MDR sensitive drug). Our results show that the parental cell line was very sensitive to paclitaxel (IC₅₀ 4 nM) but the MDR positive sub-line was greater than 100 fold resistant (IC₅₀ 750 nM). When the two cell lines were treated with **10ae**, both the parental and the MDR positive cell lines were almost equally sensitive to the cell killing activity of the compound.

Effects of **10ae** on cell cycle progression of tumor cells

Treatment of cancer cells with **10ae** results in a time dependent rounding of the cells indicative of mitotic arrest.²⁵ In order to study the cell cycle effects of **10ae** treatment we ran a series of experiments by fluorescence-activated cell sorting (FACS) and signal transduction studies using human prostate cancer cells. DU145 cells which are androgen negative prostate cancer cells were treated with increasing concentrations of **10ae** for 24 h. Since these cells were one of the more sensitive cell lines tested, and since DU145 cells have a very predictable cell cycle time making them suitable for cell cycle analysis, these cells were used for the following experiment.^{26–28} Cell cycle analysis performed by FACS analysis revealed that the cells accumulated in G2/M phase of the cell cycle in a concentration-dependent manner. Results presented in Figure 1 show that treatment with 0.25 μ M of **10ae** resulted in the accumulation of tumor cells in the G2/M phase of the cell cycle with a majority of cells showing G2/M arrest, when treated with 0.5 μ M concentration of the compound. The FACS analysis determined that the treated cells had greater than 2N amount of DNA but did not differentiate between G₂ and mitotic phases of the cell cycle. Based on these results we next studied the effects of **10ae** on the phosphorylation status of proteins known to be important markers of mitotic arrest and spindle checkpoint activation. Hela cells derived from a human cervical tumor which have been extensively studied as a model cell line for mitotic inhibitors²⁹ were treated with 1 μ M concentration of **10ae** for various time points and the pattern of expression of Histone H3 and its phosphorylated mitotic (ser10) form were analyzed. Phosphorylation of Histone H3 (ser10) is a widely accepted indicator of mitotic arrest as well as a diagnostic tool for the mitotic index of

tumors.^{30–33} As shown in figure 2, increased levels of phospho-histone H3 were observed within 6 h after treatment with maximal accumulation at 24 h (121 maximum fold increase). Phosphorylation of BCL-2 has also been known to be a marker for mitosis,³⁴ and this protein became phosphorylated at the same time as histone H3 (88 fold). Concurrently to the accumulation of phospho-histone H3, the protein levels of both cyclin B1 (2.5 fold) and PLK-1 (2.5 fold) increased after 6 h of treatment. The expression of these proteins is known to be closely linked to progression through mitosis.^{35–37} Phosphorylation of BubR1 is a useful marker of mitotic arrest due to the activation of the spindle checkpoint,^{38,39} so we next analyzed the phosphorylation status of this protein. Similar to histone H3 and Bcl-2, BubR1 (2.95 fold) became phosphorylated at 6 h following treatment of cancer cells with **10ae**. Taken together, these data strongly suggest that **10ae** treatment induces a mitotic arrest, with the activation of spindle checkpoint within 6 h of treatment.

Compound 10ae induces apoptosis in tumor cells

Tumor cells treated with **10ae** accumulated in the G2/M phase of the cell cycle in a dosedependent manner and appeared to be unable to exit from this phase, leading to the activation of apoptotic pathways as judged by PARP [Poly(ADP-ribose) polymerase-1] cleavage⁴⁰ which is a marker for caspase activation (Figure 3).

Compound 10ae kills tumor cells by stabilizing microtubules

The polymerization of microtubules from purified tubulin can be monitored *in vitro* by measuring an increase in light scattering. This *in vitro* experiment removes complicating factors, such as microtubule-associated proteins (MAPs), which might be part of a putative target that leads to disruption of microtubules as observed with microscopy. To test our hypothesis that the target of (Z)-1-Aryl-3-arylamino-2-propen-1-one (**10**) is tubulin, and not a MAP, we monitored the polymerization of tubulin after treatment with **10ag**, **10ah** and **10ae** (Figure 4). In this experiment, paclitaxel, a microtubule stabilizer, enhanced the rate of tubulin polymerization, while vincristine, a microtubule destabilizer, prevented the polymerization of tubulin. Similar to paclitaxel, **10ag**, **10ah** and **10ae** stabilized tubulin polymerization at 1 μ M. Compound **10ae** was most potent in cytotoxicity assay compared to the other analogues and also from the fig. 4, **10ae** is superior to paclitaxel in that it causes more microtubule assembly at the same concentration (1 μ M). Thus, the enaminone based compounds stabilize the formation of microtubules *in vitro*.

Compound 10ae treatment induces abnormal mitotic spindle development

Since **10ae** was found to alter tubulin *in vitro* polymerization kinetics, we next examined the mitotic spindle apparatus in cancer cells treated with **10ae**. HeLa cells were treated with **10ae** for 18 hours and fixed and stained for alpha-tubulin. Figure 5 shows that HeLa cells became arrested in mitosis and the mitotic cells had abnormal mitotic spindles. When cells were treated with the 0.25 μ M of **10ae**, near the GI50 value, the mitotic cells displayed an atypical bipolar metaphase plate in which the tubulin appeared bundled at the poles and some chromosomes were not attached aligned at the metaphase plate (see arrows). When the cells were treated with higher concentrations of **10ae**, the mitotic cells acquired multiple tubulin bundles (multipolar) without chromosomes aligned at the metaphase plate with more dispersion of the chromosomes. We compared the mitotic spindle phenotype to cells treated with paclitaxel, tubulin stabilizer, and to cells treated with vincristine, a tubulin depolymerizer. As shown in figure 5, **10ae** treatment is unique in its effect on mitotic spindle formation, in that although the mitotic cells multipolar which is similar to paclitaxel, the intensity of the tubulin staining is lower and the the chromosome spreads are different. At lower concentrations, **10ae** was similar to paclitaxel in that unbound chromosomes were observed outside the metaphase plate while higher concentrations resulted in a more

dispersed chromosome spread with 3 or more tubulin bundles. When one compares **10ae** to vincristine treated cells, it is clear that **10ae** is not destabilizing tubulin since we do not observe complete loss of tubulin staining.

The effects of **10ae** treatment on tubulin stability can also be examined by analysis of the tubulin organization of non-mitotic interphase cells. Figure 6 shows that treatment with high concentrations of **10ae** did not result in an overall disruption of cytoplasmic microtubule organization as evident in cells treated vincristine. The microtubule organization appeared to be somewhat shortened throughout the cytoplasm, but the overall protofilament structure was still intact. Paclitaxel treatment resulted in bundling of the microtubule fibers near the nucleus, this was not observed with **10ae** treatment. This data suggests that **10ae** treatment does not depolymerize tubulin but interferes with microtubule spindle development during mitosis without altering cytoplasmic microtubules resulting in a mitotic block and cell death.

Conclusion

In this communication, we describe the synthesis of a series of (*Z*)-1-Aryl-3-arylamino-2-propen-1-ones (**10**) molecules, which induce apoptotic death of a wide variety of human tumor cell lines at nanomolar concentrations by promoting tubulin polymerization and stabilizing microtubules. This is a first report that shows a group of small synthetic molecules (**10**) behave like paclitaxel and epothilones in tumor cell killing in nano molar range by promoting tubulin polymerization and microtubule stabilization *in vitro*. Our studies show that the cytotoxic activity of the (*Z*)-1-Aryl-3-arylamino-2-propen-1-ones (**10**) is completely dependent on the nature and position of the substituents on the two aromatic rings. These structure function studies show that a molecule with an aniline ring having 3-hydroxy, 4-methoxy groups and a benzoyl ring with a bromine atom at ortho and methoxy groups at 3, 4 and 5-positions (**10ae**) showed optimum biological activity. Biological evaluation of the activity of **10ae** shows that this compound is highly active against a wide variety of human tumor cell lines including those that are resistant to the activity of many of the currently used chemotherapeutic agents.

Experimental Section

Chemistry: General Methods

All reagents and solvents were obtained from commercial suppliers and used without further purification unless otherwise stated. Solvents were dried using standard procedures and reactions requiring anhydrous conditions were performed under N₂ atmosphere. Reactions were monitored by Thin Layer Chromatography (TLC) on preloaded silica gel F254 plates (Sigma-Aldrich) with a UV indicator. Column chromatography was performed with Merck 70–230 mesh silica gel 60 A. Yields were of purified product and were not optimized. Melting points were determined using an Electro thermal Mel-Temp 3.0 micro melting point apparatus and are uncorrected. ¹H NMR spectra were obtained with a Bruker AM 300 and 400 MHz spectrometer. The chemical shifts are reported in parts per million (δ) downfield using tetramethylsilane (SiMe₄) as internal standard. Spin multiplicities are given as s (singlet), d (doublet), dd (double doublet) brs (broad singlet), m (multiplet), and q (quartet). Coupling constants (J values) were measured in hertz (Hz). All LC/MS data were gathered on an Agilent 1200 LC with Agilent 6410 triple quadrupole mass spectrometer detectors. The compound solution was infused into the electrospray ionization source operating positive and negative modes in methanol:water: TFA (50:50:0.1% v/v) at 0.4ml/min. The sample cone (declustering) voltage was set at 100 V. The instrument was externally calibrated for the mass range m/z 100 to m/z 1000. The purity of the final compounds was determined by HPLC and is 95% or higher unless specified otherwise.

Synthesis of 2-Chloro-3,4,5-trimethoxybenzaldehyde (2)—3,4,5-

trimethoxybenzaldehyde **1c** (1.0 g, 5 mmol) was dissolved in 25 mL of dichloromethane and sulfonyl chloride (0.49 mL, 6.1 mmol) was added and stirred at 10 °C for 2 h. After reaction was completed (checked by TLC) the solvent was concentrated under vacuum and washed with hexane to get pure 2-chloro-3,4,5- trimethoxybenzaldehyde **2** with 60% yield. Semi solid; ¹H NMR (CDCl₃, 300 MHz): δ 3.91 (s, 3H, OCH₃), 3.93 (s, 3H, OCH₃), 3.99 (s, 3H, OCH₃), 7.27 (s, 1H, Ar-H), 10.39 (s, 1H, H-C=O). MS found (M+H)⁺ (m/z): 231.20, Calcd for C₁₀H₁₁ClO₄ m/z: 230.03.

Synthesis of 2-Bromo-3,4,5-trimethoxybenzaldehyde (3)—To a solution of 3,4,5-trimethoxy benzaldehyde **1c** (5.0 g, 25.4 mmol) in 50 mL chloroform (CHCl₃), was added Nbromosuccinimide (5.44 g, 30.5 mmol). The solution was heated at reflux temperature for 3 h. After the reaction was completed by TLC reaction mixture was brought to room temperature, the solution was washed with water and extracted with diethyl ether (Et₂O). The combined extracts were dried with anhydrous Na₂SO₄ and concentrated. The crude bromobenzaldehyde was recrystallized from hexanes and Et₂O to get pure white solid with 97% yield. mp 69–70 °C; ¹H NMR (CDCl₃, 300 MHz): δ 3.90 (s, 3H, OCH₃), 3.92 (s, 6H, OCH₃), 7.30 (s, 1H, Ar-H), 10.15 (s, 1H, H-C=O). MS found (M+H)⁺ (m/z): 275.10, Calcd for C₁₀H₁₁BrO₄ m/z: 273.98.

Synthesis of 3,4,5-Trimethoxy-2-nitrobenzaldehyde (6)

Step 1: Synthesis of (3,4,5-Trimethoxy- 2-nitrophenyl)methanol (5): Methyl 3,4,5-trimethoxy-2-nitrobenzoate **4** (1.5 g, 3.69 mmol) was dissolved in 20 mL of anhydrous toluene, cooled to –50 °C and treated with a solution of diisobutylaluminum hydride (1.0 M solution in hexane, 4.6 mL, 4.6 mmol) over a period of 10 min. After 30 min the reaction was quenched with 10 mL of methanol and brought to room temperature. The resulting reaction mixture was diluted with water and extracted with ethyl acetate. The extract was dried over anhydrous Na₂SO₄ and concentrated under vacuum to give (3,4,5-Trimethoxy-2-nitrophenyl)methanol **5** which was purified by column chromatography (silica gel, 30% ethyl acetate in hexane, R_f= 0.33) as brown solid with 55% yield. mp 59–60 °C; ¹H NMR (CDCl₃, 300 MHz): δ 2.34 (brs, 1H, OH), 3.90 (s, 3H, OCH₃), 3.95 (s, 3H, OCH₃), 4.00 (s, 3H, OCH₃), 6.85 (s, 1H, Ar-H). MS found (M+H)⁺ (m/z): 244.10, Calcd for C₁₀H₁₃NO₆ m/z: 243.07.

Step 2: Synthesis of 3,4,5-Trimethoxy-2-nitrobenzaldehyde (6): The compound **5** (1.0 g, 4.1 mmol) was dissolved in 50 mL chloroform to which MnO₂ (2.14 g, 24.6 mmol) was added and stirred for overnight and additional portion of MnO₂ (0.53 g, 6.15 mmol) was added and stirred for 12 h. The solids were removed by filtration through a celite pad and washed with chloroform. The chloroform was evaporated in vacuo to get pure compound **6** as brown solid with 63% yield. mp 64–65 °C; ¹H NMR (CDCl₃, 300 MHz): δ 3.91 (s, 3H, OCH₃), 3.93 (s, 6H, OCH₃), 7.15 (s, 1H, Ar-H), 9.80 (s, 1H, H-C=O). MS found (M+H)⁺ (m/z): 242.20, Calcd for C₁₀H₁₁NO₆ m/z: 241.06.

General procedure for the synthesis of 1-aryl-2-propyn-1-ol (7)

A solution of aldehyde **1– 6** (5 mmol) in dry tetrahydrofuran (THF) was added to a stirred solution of ethynylmagnesium bromide in THF (0.5 M solution, 7.5 mmol) at 0 °C. The solution was stirred at 0 °C temperature for 2 h then warmed to room temperature and stirred for another 6 -7 h. Saturated aqueous ammonium chloride solution 5 mL was added, the mixture was evaporated in vacuo and partitioned between ethyl acetate and saturated ammonium chloride solution. The organic layer was washed with brine, dried over anhydrous Na₂SO₄ and evaporated in vacuo to get pure compounds and were used for next step without further purification.

1-(4-Methoxyphenyl)prop-2-yn-1-ol (7a)—Starting from 4-methoxybenzaldehyde **1a**, 70% of **7a** was obtained according to the method described in general procedure **7**. liquid; ^1H NMR (CDCl_3 , 400 MHz): δ 2.65 (d, 1H, $J = 2.2$ Hz, $\equiv\text{-H}$), 3.79 (s, 3H, OCH_3), 5.37–5.40 (m, 1H, H-C-OH), 6.87–6.90 (m, 2H, Ar-H), 7.43–7.47 (m, 2H, Ar-H). MS found $(\text{M-H}_2\text{O}+\text{H})^+$ (m/z): 145.20, Calcd for $\text{C}_{10}\text{H}_{10}\text{O}_2$ m/z: 162.07.

1-(2,4,6-Trimethoxyphenyl)prop-2-yn-1-ol (7b)—Starting from 2,4,6-trimethoxybenzaldehyde **1b**, 65% of **7b** was obtained as brown solid according to the method described in general procedure **7**. mp 119–120 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 2.42 (d, 1H, $J = 2.3$ Hz, $\equiv\text{-H}$), 3.80 (s, 3H, OCH_3), 3.86 (s, 6H, OCH_3), 5.80–5.84 (m, 1H, H-C-OH), 6.14 (s, 2H, Ar-H). MS found $(\text{M-H}_2\text{O}+\text{H})^+$ (m/z): 205.30, Calcd for $\text{C}_{12}\text{H}_{14}\text{O}_4$ m/z: 222.09.

1-(3,4,5-Trimethoxyphenyl)prop-2-yn-1-ol (7c)—Starting from 3,4,5-trimethoxybenzaldehyde **1c**, 65% of **7c** was obtained as brown solid according to the method described in general procedure **7**. mp 51–52 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 2.62 (d, 1H, $J = 2.1$ Hz, $\equiv\text{-H}$), 3.83 (s, 3H, OCH_3), 3.86 (s, 6H, OCH_3), 5.39–5.54 (m, 1H, H-C-OH), 6.77 (s, 2H, Ar-H). MS found $(\text{M-H}_2\text{O}+\text{H})^+$ (m/z): 205.20, Calcd for $\text{C}_{12}\text{H}_{14}\text{O}_4$ m/z: 222.09.

1-(2-Chloro-3,4,5-trimethoxyphenyl)prop-2-yn-1-ol (7d)—Starting from 2-chloro-3,4,5-trimethoxybenzaldehyde **1d**, 70% of **7d** was obtained as brown solid according to the method described in general procedure **7**. mp 65–66 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 2.66 (d, 1H, $J = 2.4$ Hz, $\equiv\text{-H}$), 3.89 (s, 3H, OCH_3), 3.90 (s, 6H, OCH_3), 5.79–5.80 (m, 1H, H-C-OH), 7.14 (s, 1H, Ar-H). MS found $(\text{M-H}_2\text{O}+\text{H})^+$ (m/z): 239.10, Calcd for $\text{C}_{12}\text{H}_{13}\text{ClO}_4$ m/z: 256.05.

1-(2-Bromo-3,4,5-trimethoxyphenyl)prop-2-yn-1-ol (7e)—Starting from 2-bromo-3,4,5-trimethoxybenzaldehyde **1e**, 70% of **7e** was obtained as brown solid according to the method described in general procedure **7**. mp 59–60 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 2.66 (d, 1H, $J = 2.1$ Hz, $\equiv\text{-H}$), 3.88 (s, 3H, OCH_3), 3.89 (s, 6H, OCH_3), 5.79–5.80 (m, 1H, H-C-OH), 7.18 (s, 1H, Ar-H). MS found $(\text{M-H}_2\text{O}+\text{H})^+$ (m/z): 283.20, Calcd for $\text{C}_{12}\text{H}_{13}\text{BrO}_4$ m/z: 300.00.

1-(3,4,5-Trimethoxy-2-nitrophenyl)prop-2-yn-1-ol (7f)—Starting from 2-nitro-3,4,5-trimethoxybenzaldehyde **1f**, 60% of **7f** was obtained as brown solid according to the method described in general procedure **7**. mp 75–76 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 2.50 (d, 1H, $J = 2.2$ Hz, $\equiv\text{-H}$), 3.72 (s, 3H, OCH_3), 3.77 (s, 3H, OCH_3), 3.80 (s, 3H, OCH_3), 5.42–5.42 (m, 1H, H-C-OH), 6.91 (s, 1H, Ar-H). MS found $(\text{M-H}_2\text{O}+\text{H})^+$ (m/z): 250.20, Calcd for $\text{C}_{12}\text{H}_{13}\text{NO}_6$ m/z: 267.07.

General procedure for the synthesis of 1-aryl-2-propyn-1-one (**8**)

A solution of 2-iodoxybenzoic acid (IBX) (12.5 mmol) in dimethyl sulfoxide (DMSO) (90 mL) was stirred for 5 min at room temperature until to get homogeneous. A solution of secondary alcohol **7** (5 mmol) in DMSO (5 mL) was added and the mixture was stirred for 5 h. Water (10 mL) was added and the mixture was stirred at room temperature for 10 min, cooled in ice and partitioned between water and ethyl acetate. The mixture was filtered through celite and the aqueous layer was further extracted with ethyl acetate. The organic extracts were combined, washed with water followed by saturated sodium bicarbonate solutions and brine, dried over sodium sulfate and evaporated in vacuo to get the pure product and was used for next step without further purification.

1-(4-Methoxyphenyl)prop-2-yn-1-one (8a)—Starting from 1-(4-Methoxyphenyl)prop-2-yn-1-ol **7a**, 72% of **8a** was obtained as pale yellow solid according to the method described in above mentioned general procedure **8**. mp 81–82 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.36 (s, 1H, ≡-H), 3.88 (s, 3H, OCH₃), 6.94–6.96 (m, 2H, Ar-H), 8.11–8.13 (m, 2H, Ar-H). MS found (M+H)⁺ (m/z): 161.30, Calcd for C₁₀H₈O₂ m/z: 160.05.

1-(2,4,6-Trimethoxyphenyl)prop-2-yn-1-one (8b)—Starting from 1-(2,4,6-Trimethoxyphenyl)prop-2-yn-1-ol **7b**, 70% of **8b** was obtained as pale yellow solid according to the method described in above mentioned general procedure **8**. mp 83–84 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.14 (s, 1H, ≡-H), 3.76 (s, 6H, OCH₃), 3.77 (s, 3H, OCH₃), 6.03 (s, 2H, Ar-H). MS found (M+H)⁺ (m/z): 221.20, Calcd for C₁₂H₁₂O₄ m/z: 220.07.

1-(3,4,5-Trimethoxyphenyl)prop-2-yn-1-one (8c)—Starting from 1-(3,4,5-Trimethoxyphenyl)prop-2-yn-1-ol **7c**, 70% of **8c** was obtained as pale yellow solid according to the method described in above mentioned general procedure **8**. mp 123–124 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.35 (s, 1H, ≡-H), 3.86 (s, 3H, OCH₃), 3.88 (s, 6H, OCH₃), 7.36 (s, 2H, Ar-H). MS found (M+H)⁺ (m/z): 221.20, Calcd for C₁₂H₁₂O₄ m/z: 220.07.

1-(2-Chloro-3,4,5-trimethoxyphenyl)prop-2-yn-1-one (8d)—Starting from 1-(2-Chloro-3,4,5-trimethoxyphenyl)prop-2-yn-1-ol **7d**, 70% of **8d** was obtained as brown solid according to the method described in above mentioned general procedure **8**. mp 84–85 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.50 (s, 1H, ≡-H), 3.91 (s, 3H, OCH₃), 3.93 (s, 3H, OCH₃), 3.99 (s, 3H, OCH₃), 7.44 (s, 1H, Ar-H). MS found (M+H)⁺ (m/z): 255.20, Calcd for C₁₂H₁₁ClO₄ m/z: 254.03.

1-(2-Bromo-3,4,5-trimethoxyphenyl)prop-2-yn-1-one (8e)—Starting from 1-(2-Bromo-3,4,5-trimethoxyphenyl)prop-2-yn-1-ol **7e**, 70% of **8e** was obtained as brown solid according to the method described in above mentioned general procedure **8**. mp 80–81 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.50 (s, 1H, ≡-H), 3.90 (s, 3H, OCH₃), 3.93 (s, 3H, OCH₃), 3.98 (s, 3H, OCH₃), 7.47 (s, 1H, Ar-H). MS found (M+H)⁺ (m/z): 298.90, Calcd for C₁₂H₁₁BrO₄ m/z: 297.98.

1-(3,4,5-Trimethoxy-2-nitrophenyl)prop-2-yn-1-one (8f)—Starting from 1-(3,4,5-trimethoxy-2-nitrophenyl)prop-2-yn-1-ol **7f**, 70% of **8f** was obtained as brown solid according to the method described in above mentioned general procedure **8**. mp 87–88 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.42 (s, 1H, ≡-H), 3.88 (s, 3H, OCH₃), 3.91 (s, 3H, OCH₃), 3.93 (s, 3H, OCH₃), 7.39 (s, 1H, Ar-H). MS found (M+H)⁺ (m/z): 266.30, Calcd for C₁₂H₁₁NO₆ m/z: 265.06.

General procedure for the synthesis of (Z)-1-Aryl-3-arylamino-2-propen-1-one (10)

The ethynylketone **8** (5 mmol), was dissolved in absolute ethanol and arylamine (5 mmol) was added. The reaction was stirred for 4 h at room temperature. After the completion of reaction (checked by TLC), the reaction mixture was diluted with water and filtered the product. The crude product was recrystallized from methanol to get pure compound **10**.

(Z)-1-(4-Methoxyphenyl)-3-(4-methoxyphenylamino)prop-2-en-1-one (10a)—Starting from 1-(4-methoxyphenyl)prop-2-yn-1-one **8a** and 4-methoxyphenylamine, 76% of **10a** was obtained as yellow solid according to above mentioned general procedure **10**. R_f= 0.71 (30% ethyl acetate in hexane). mp 187–188 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.80 (s,

3H, OCH₃), 3.86 (s, 3H, OCH₃), 5.94 (d, 1H, *J* = 7.8 Hz, COCH=), 6.88–6.95 (m, 4H, Ar-H), 7.02–7.05 (m, 2H, Ar-H), 7.37–7.42 (dd, 1H, *J* = 7.8, 12.3 Hz, =CH-NH), 7.90–7.93 (m, 2H, Ar-H), 12.06 (d, 1H, *J* = 12.1 Hz, NH). MS found (M+H)⁺ (m/z): 284.20, Calcd for C₁₇H₁₇NO₃ m/z: 283.12.

(Z)-1-(4-Methoxyphenyl)-3-(3,4,5-trimethoxyphenylamino)prop-2-en-1-one

(10b)—Starting from 1-(4-methoxyphenyl)prop-2-yn-1-one **8a** and 3,4,5-trimethoxyphenylamine, 74% of **10b** was obtained as yellow solid according to above mentioned general procedure **10**. *R*_f = 0.43 (30% ethyl acetate in hexane). mp 100–101 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.82 (s, 3H, OCH₃), 3.87 (s, 9H, OCH₃), 5.98 (d, 1H, *J* = 12.9 Hz, COCH=), 6.31 (s, 2H, Ar-H), 6.94–6.99 (m, 2H, Ar-H), 7.39–7.44 (dd, 1H, *J* = 7.8, 12.3 Hz, =CH-NH), 7.91–7.94 (m, 2H Ar-H), 12.12 (d, 1H, *J* = 12.0 Hz, NH). MS found (M+H)⁺ (m/z): 344.20, Calcd for C₁₉H₂₁NO₅ m/z: 343.14.

(Z)-3-(4-Methoxyphenylamino)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one

(10c)—Starting from 1-(2,4,6-trimethoxyphenyl)prop-2-yn-1-one **8b** and 4-methoxyphenylamine, 77% of **10c** was obtained as yellow solid according to above mentioned general procedure **10**. *R*_f = 0.28 (30% ethyl acetate in hexane). mp 130–131 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.80 (s, 6H, OCH₃), 3.82 (s, 3H, OCH₃), 3.84 (s, 3H, OCH₃), 5.52 (d, 1H, *J* = 7.7 Hz, COCH=), 6.14 (s, 2H, Ar-H), 6.95–6.98 (m, 2H, Ar-H), 7.20–7.26 (m, 1H, =CH-NH & 2H, Ar-H), 11.86 (d, 1H, *J* = 12.2 Hz, NH). MS found (M+H)⁺ (m/z): 344.20, Calcd for C₁₉H₂₁NO₅ m/z: 343.14.

(Z)-3-(2-Hydroxyphenylamino)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one

(10d)—Starting from 1-(2,4,6-trimethoxyphenyl)prop-2-yn-1-one **8b** and 2-aminophenol, 69% of **10d** was obtained as yellow solid according to above mentioned general procedure **10**. *R*_f = 0.10 (30% ethyl acetate in hexane). mp 164–165 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.47 (s, 6H, OCH₃), 3.56 (s, 3H, OCH₃), 5.27 (d, 1H, *J* = 7.4 Hz, COCH=), 5.85 (s, 2H, Ar-H), 6.43–6.54 (m, 3H, Ar-H), 6.80–6.82 (m, 1H, Ar-H), 7.08–7.13 (dd, 1H, *J* = 7.6, 12.8 Hz, =CH-NH), 11.85 (d, 1H, *J* = 12.2 Hz, NH). MS found (M+H)⁺ (m/z): 330.20, Calcd for C₁₈H₁₉N₂O₅ m/z: 329.13.

(Z)-3-(4-Chlorophenylamino)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one (10e)

—Starting from 1-(2,4,6-trimethoxyphenyl)prop-2-yn-1-one **8b** and 4-chlorophenylamine, 72% of **10e** was obtained as yellow solid according to above mentioned general procedure **10**. *R*_f = 0.26 (30% ethyl acetate in hexane). mp 180–181 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.80 (s, 6H, OCH₃), 3.84 (s, 3H, OCH₃), 5.54 (d, 1H, *J* = 7.8 Hz, COCH=), 6.13 (s, 2H, Ar-H), 6.97–7.00 (m, 2H, Ar-H), 7.23–7.28 (m, 1H, =CH-NH & 2H, Ar-H), 11.85 (d, 1H, *J* = 12.1 Hz, NH). MS found (M+H)⁺ (m/z): 348.20, Calcd for C₁₈H₁₈ClNO₄ m/z: 347.09.

(Z)-3-(2,4-Dimethoxyphenylamino)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one

(10f)—Starting from 1-(2,4,6-trimethoxyphenyl)prop-2-yn-1-one **8b** and 2,4-dimethoxyphenylamine, 70% of **10f** was obtained as yellow solid according to above mentioned general procedure **10**. *R*_f = 0.10 (30% ethyl acetate in hexane). mp 105–106 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.79 (s, 6H, OCH₃), 3.84 (s, 6H, OCH₃), 3.89 (s, 3H, OCH₃), 5.47 (d, 1H, *J* = 7.6 Hz, COCH=), 6.12 (s, 2H, Ar-H), 6.44–6.50 (m, 2H, Ar-H), 7.03 (d, 1H, *J* = 8.6 Hz, Ar-H), 7.27–7.33 (dd, 1H, *J* = 7.6, 12.8 Hz, =CH-NH), 11.90 (d, 1H, *J* = 12.1 Hz, NH). MS found (M+H)⁺ (m/z): 374.30, Calcd for C₂₀H₂₃NO₆ m/z: 373.15.

(Z)-1-(2,4,6-Trimethoxyphenyl)-3-(2,4,6-trimethoxyphenylamino)prop-2-en-1-one

(10g)—Starting from 1-(2,4,6-trimethoxyphenyl)prop-2-yn-1-one **8b** and 2,4,6-trimethoxyphenylamine, 80% of **10g** was obtained as yellow solid according to above

mentioned general procedure **10**. R_f = 0.06 (30% ethyl acetate in hexane). mp 129–130 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 3.78 (s, 6H, OCH_3), 3.80 (s, 3H, OCH_3), 3.82 (s, 3H, OCH_3), 3.86 (s, 6H, OCH_3), 5.35 (d, 1H, J = 7.5 Hz, COCH=), 6.12 (s, 2H, Ar-H), 6.17 (s, 2H, Ar-H), 7.85–7.90 (dd, 1H, J = 7.5, 12.7 Hz, $=\text{CHNH}$), 12.00 (d, 1H, J = 12.2 Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 404.20, Calcd for $\text{C}_{21}\text{H}_{25}\text{NO}_7$ m/z : 403.16.

(Z)-1-(2,4,6-Trimethoxyphenyl)-3-(3,4,5-trimethoxyphenylamino)prop-2-en-1-one (10h)

—Starting from 1-(2,4,6-trimethoxyphenyl)prop-2-yn-1-one **8b** and 3,4,5-trimethoxyphenylamine, 75% of **10h** was obtained as yellow solid according to above mentioned general procedure **10**. R_f = 0.08 (30% ethyl acetate in hexane). mp 177–178 °C; ^1H NMR (CDCl_3 , 300 MHz): δ 3.82–3.90 (m, 18H, OCH_3), 5.55 (d, 1H, J = 7.6 Hz, COCH=), 6.19 (s, 2H, Ar-H), 6.40 (s, 2H, Ar-H), 7.30–7.37 (dd, 1H, J = 7.6, 12.8 Hz, $=\text{CH-NH}$), 11.98 (d, 1H, J = 12.3 Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 404.20, Calcd for $\text{C}_{21}\text{H}_{25}\text{NO}_7$ m/z : 403.16.

(Z)-3-(2-Hydroxyphenylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10i)

—Starting from 1-(3,4,5-Trimethoxyphenyl)prop-2-yn-1-one **8c** and 2-aminophenol, 72% of **10i** was obtained as yellow solid according to above mentioned general procedure **10**. R_f = 0.22 (30% ethyl acetate in hexane). mp 190–191 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 3.89 (s, 3H, OCH_3), 3.93 (s, 6H, OCH_3), 6.02 (d, 1H, J = 7.7 Hz, COCH=), 6.91 (s, 2H, Ar-H), 7.18–7.26 (m, 4H, Ar-H), 7.57–7.62 (dd, 1H, J = 7.7, 12.8 Hz, $=\text{CH-NH}$), 12.35 (d, 1H, J = 12.4 Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 330.20, Calcd for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_5$ m/z : 329.13.

(Z)-3-(3-Hydroxyphenylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10j)

—Starting from 1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8c** and 3-aminophenol, 70% of **10j** was obtained as yellow solid according to above mentioned general procedure **10**. R_f = 0.64 (50% ethyl acetate in hexane). mp 120–121 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 3.74 (s, 3H, OCH_3), 3.76 (s, 6H, OCH_3), 5.36 (s, 1H, OH), 5.80 (d, 1H, J = 7.8 Hz, COCH=), 6.38–6.51 (m, 3H, Ar-H), 7.01–7.05 (m, 3H, Ar-H), 7.28–7.33 (dd, 1H, J = 8.0, 12.3 Hz, $=\text{CH-NH}$), 11.88 (d, 1H, J = 12.3 Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 330.10, Calcd for $\text{C}_{18}\text{H}_{19}\text{NO}_5$ m/z : 329.13.

(Z)-3-(2-Methoxyphenylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10k)

—Starting from 1-(3,4,5-Trimethoxyphenyl)prop-2-yn-1-one **8c** and 2-methoxyphenylamine, 81% of **10k** was obtained as yellow solid according to above mentioned general procedure **10**. R_f = 0.46 (30% ethyl acetate in hexane). mp 118–119 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 3.84 (s, 3H, OCH_3), 3.86 (s, 6H, OCH_3), 3.91 (s, 3H, OCH_3), 5.94 (d, 1H, J = 7.8 Hz, COCH=), 6.85–6.97 (m, 4H Ar-H), 7.16 (s, 2H, Ar-H), 7.44–7.49 (dd, 1H, J = 7.6, 12.6 Hz, $=\text{CH-NH}$), 12.10 (d, 1H, J = 12.1 Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 344.20, Calcd for $\text{C}_{19}\text{H}_{21}\text{NO}_5$ m/z : 343.14.

(Z)-3-(4-Methoxyphenylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10l)

—Starting from 1-(3,4,5-Trimethoxyphenyl)prop-2-yn-1-one **8c** and 4-methoxyaniline, 82% of **10l** was obtained as yellow solid according to above mentioned general procedure **10**. R_f = 0.40 (30% ethyl acetate in hexane). mp 107–108 °C; ^1H NMR (CDCl_3 , 300 MHz): δ 3.81 (s, 3H, OCH_3), 3.91 (s, 3H, OCH_3), 3.94 (s, 6H, OCH_3), 5.93 (d, 1H, J = 7.8 Hz, COCH=), 6.89–6.92 (m, 2H, Ar-H), 7.04–7.07 (m, 2H, Ar-H), 7.20 (s, 2H, Ar-H), 7.41–7.48 (dd, 1H, J = 7.8, 12.3 Hz, $=\text{CHNH}$), 12.18 (d, 1H, J = 12.3 Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 344.20, Calcd for $\text{C}_{19}\text{H}_{21}\text{NO}_5$ m/z : 343.14.

(Z)-3-(4-Chlorophenylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10m)

—Starting from 1-(3,4,5-Trimethoxyphenyl)prop-2-yn-1-one **8c** and 4-chlorophenylamine,

72% of **10m** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.80$ (50% ethyl acetate in hexane). mp 147–148 °C; ^1H NMR (CDCl_3 , 300 MHz): δ 3.92 (s, 3H, OCH_3), 3.94 (s, 6H, OCH_3), 6.01 (d, 1H, $J = 8.1$ Hz, COCH=), 7.02–7.05 (m, 2H, Ar-H), 7.20 (s, 2H, Ar-H), 7.30–7.33 (m, 2H, Ar-H), 7.42–7.49 (dd, 1H, $J = 7.8, 12.3$ Hz, $=\text{CH-NH}$), 12.13 (d, 1H, $J = 12.3$ Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 348.10, Calcd for $\text{C}_{18}\text{H}_{18}\text{ClNO}_4$ m/z : 347.09.

(Z)-3-(4-Trifluoromethoxyphenylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10n)—Starting from 1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8c** and 4-trifluoromethoxyphenylamine 75% of **10n** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.80$ (50% ethyl acetate in hexane). mp 107–108 °C; ^1H NMR (CDCl_3 , 300 MHz): δ 3.92 (s, 3H, OCH_3), 3.94 (s, 6H, OCH_3), 6.02 (d, 1H, $J = 7.8$ Hz, COCH=), 7.08–7.12 (m, 2H, Ar-H), 7.20–7.24 (m, 4H, Ar-H), 7.42–7.47 (dd, 1H, $J = 8.1, 12.3$ Hz, $=\text{CH-NH}$), 12.15 (d, 1H, $J = 12.0$ Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 398.10, Calcd for $\text{C}_{19}\text{H}_{18}\text{F}_3\text{NO}_5$ m/z : 397.11.

(Z)-3-(4-Trifluoromethylphenylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10o)—Starting from 1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8c** and 4-trifluoromethylphenylamine, 68% of **10o** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.80$ (50% ethyl acetate in hexane). mp 92–93 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 3.86 (s, 3H, OCH_3), 3.87 (s, 6H, OCH_3), 6.01 (d, 1H, $J = 8.0$ Hz, COCH=), 7.10 (d, 2H, $J = 8.4$ Hz, Ar-H), 7.15 (s, 2H, Ar-H), 7.43–7.48 (dd, 1H, $J = 8.0, 12.0$ Hz, $=\text{CH-NH}$), 7.58 (d, 2H, $J = 8.5$ Hz, Ar-H), 12.05 (d, 1H, $J = 12.3$ Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 382.20, Calcd for $\text{C}_{19}\text{H}_{18}\text{F}_3\text{NO}_4$ m/z : 381.12.

(Z)-3-(3-Hydroxy-4-methoxyphenylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10p)—Starting from 1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8c** and 2-methoxy-5-aminophenol, 70% of **10p** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.26$ (30% ethyl acetate in hexane). mp 142–143 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 3.59 (s, 3H, OCH_3), 3.62 (s, 3H, OCH_3), 3.65 (s, 6H, OCH_3), 5.64 (d, 1H, $J = 7.7$ Hz, COCH=), 6.28–6.31 (m, 1H, Ar-H), 6.46 (d, 1H, $J = 2.6$ Hz, Ar-H), 6.53 (d, 1H, $J = 8.6$ Hz, Ar-H), 6.91 (s, 2H, Ar-H), 7.10–7.15 (dd, 1H, $J = 7.7, 12.3$ Hz, $=\text{CH-NH}$), 11.80 (d, 1H, $J = 12.1$ Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 360.10, Calcd for $\text{C}_{19}\text{H}_{21}\text{NO}_6$ m/z : 359.14.

Synthesis of (Z)-3-(3-Amino-4-methoxyphenylamino)-1-(3,4,5-trimethoxyphenyl)-prop-2-en-1-one (10q)

Step 1: Synthesis of (Z)-3-(4-nitro-3-methoxyphenylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one: The ethynylketone **8c** (1.94 g, 5 mmol), was dissolved in absolute ethanol and 4-methoxy-3-nitrophenylamine (0.84 g, 5 mmol) was added. The reaction was stirred for 4 h at room temperature. After the completion of reaction by TLC, the reaction mixture was diluted with water and filtered the product. The crude product was recrystallized from methanol to get pure compound with 74% yield as yellow solid, $R_f = 0.40$ (30% ethyl acetate in hexane). mp 115–116 °C; ^1H NMR (CDCl_3 , 300 MHz): δ 3.93 (s, 3H, OCH_3), 3.96 (s, 3H, OCH_3), 3.98 (s, 6H, OCH_3), 6.05 (d, 1H, $J = 7.8$ Hz, COCH=), 7.13 (d, 1H, $J = 9$ Hz, Ar-H), 7.21 (s, 2H, Ar-H), 7.28–7.30 (m, 2H, Ar-H), 7.42–7.46 (dd, 1H, $J = 7.8, 12.6$ Hz, $=\text{CH-NH}$), 12.22 (d, 1H, $J = 11.7$ Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 389.20, Calcd for $\text{C}_{19}\text{H}_{20}\text{N}_2\text{O}_7$ m/z : 388.13.

Step 2: Synthesis of (Z)-3-(3-Amino-4-methoxyphenylamino)-1-(3,4,5-trimethoxyphenyl)-prop-2-en-1-one (10q): The above nitro compound (2.0 g, 5.11 mmol) obtained from step1 was dissolved in acetone: water (2:1 ratio) 100 mL and heated to 50 °C

for 30 min. After completion of the reaction by TLC, the contents were cooled to room temperature and reaction mixture was extracted with ethyl acetate. The organic extract was washed with water, brine solution and dried over anhydrous Na_2SO_4 and concentrated under vacuum to get crude product. The pure product **10q** was obtained by flash chromatography, $R_f = 0.22$ (30% ethyl acetate in hexane). Yield: 69%; Yellow solid, mp 98–99 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 3.65 (s, 3H, OCH_3), 3.72 (s, 3H, OCH_3), 3.73–3.79 (m, 6H, OCH_3 & 2H, NH_2), 5.70 (d, 1H, $J = 7.7$ Hz, COCH=), 6.25–6.30 (m, 2H, Ar-H), 6.55 (d, 1H, $J = 8.4$ Hz, Ar-H), 7.00 (s, 2H, Ar-H), 7.19–7.24 (dd, 1H, $J = 7.7, 12.5$ Hz, $=\text{CH-NH}$), (d, 1H, $J = 12.0$ Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 359.20, Calcd for $\text{C}_{19}\text{H}_{22}\text{N}_2\text{O}_5$ m/z: 358.15.

(Z)-3-(3-Fluoro-4-methoxyphenylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10r)—Starting from 1-(3,4,5-trimethoxyphenyl)-propynone **8c** and 3-fluoro-4-methoxyaniline, 68% of **10r** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.40$ (30% ethyl acetate in hexane). mp 110–111 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 4.05 (s, 3H, OCH_3), 4.08 (s, 3H, OCH_3), 4.10 (s, 6H, OCH_3), 6.13 (d, 1H, $J = 7.8$ Hz, COCH=), 6.98–7.14 (m, 3H, Ar-H), 7.36 (s, 2H, Ar-H), 7.51–7.56 (dd, 1H, $J = 7.8, 12.2$ Hz, $=\text{CH-NH}$), 12.0 (d, 1H, $J = 12.1$ Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 362.20, Calcd for $\text{C}_{19}\text{H}_{20}\text{FNO}_5$ m/z: 361.13.

(Z)-3-(3-Chloro-4-methoxyphenylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10s)—Starting from 1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8c** and 3-chloro-4-methoxyphenylamine, 70% of **10s** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.66$ (50% ethyl acetate in hexane). mp 133–134 °C; ^1H NMR (CDCl_3 , 300 MHz): δ 3.90 (s, 3H, OCH_3), 3.91 (s, 3H, OCH_3), 3.94 (s, 6H, OCH_3), 5.96 (d, 1H, $J = 7.8$ Hz, COCH=), 6.90–6.99 (m, 2H, Ar-H), 7.17 (d, 1H, $J = 2.5$ Hz, Ar-H), 7.19 (s, 2H, Ar-H), 7.35–7.42 (dd, 1H, $J = 7.6, 12.6$ Hz, $=\text{CH-NH}$), 12.15 (d, 1H, $J = 12.3$ Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 378.20, Calcd for $\text{C}_{19}\text{H}_{20}\text{ClNO}_5$ m/z: 377.10.

(Z)-3-(2-Chloro-5-hydroxyphenylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10t)—Starting from 1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8c** and 3-amino-4-chlorophenol, 73% of **10t** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.56$ (50% ethyl acetate in hexane). mp 99–100 °C; ^1H NMR (CDCl_3 , 300 MHz): δ 3.87 (s, 3H, OCH_3), 3.88 (s, 6H, OCH_3), 6.02 (d, 1H, $J = 8.0$ Hz, COCH=), 6.40–6.42 (m, 1H, Ar-H), 6.67 (d, 1H, $J = 2.1$ Hz, Ar-H), 7.16 (s, 2H, Ar-H), 7.34–7.36 (m, 1H, $=\text{CH-NH}$ & 1H, Ar-H), 12.20 (d, 1H, $J = 12.2$ Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 364.10, Calcd for $\text{C}_{18}\text{H}_{18}\text{ClNO}_5$ m/z: 363.09.

(Z)-1-(3,4,5-Trimethoxyphenyl)-3-(2,4,6-trimethoxyphenylamino)prop-2-en-1-one (10u)—Starting from 1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8c** and 2,4,6-trimethoxyphenylamine, 80% of **10u** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.20$ (30% ethyl acetate in hexane). mp 132–133 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 3.78 (s, 3H, OCH_3), 3.86 (s, 6H, OCH_3), 3.87 (s, 3H, OCH_3), 3.89 (s, 6H, OCH_3), 5.81 (d, 1H, $J = 7.7$ Hz, COCH=), 6.16 (s, 2H, Ar-H), 7.17 (s, 2H, Ar-H), 7.89–7.94 (dd, 1H, $J = 7.6, 12.7$ Hz, $=\text{CHNH}$), 12.05 (d, 1H, $J = 12.1$ Hz, NH). MS found $(\text{M}+\text{H})^+$ (m/z): 404.10, Calcd for $\text{C}_{21}\text{H}_{25}\text{NO}_7$ m/z: 403.16.

(Z)-1-(3,4,5-Trimethoxyphenyl)-3-(3,4,5-trimethoxyphenylamino)prop-2-en-1-one (10v)—Starting from 1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8c** and 3,4,5-trimethoxyphenylamine, 78% of **10v** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.22$ (30% ethyl acetate in hexane). mp 181–182 °C; ^1H NMR (CDCl_3 , 400 MHz): δ 3.75 (s, 3H, OCH_3), 3.80 (s, 6H, OCH_3), 3.84 (s, 3H, OCH_3), 3.87 (s, 6H, OCH_3), 5.90 (d, 1H, $J = 7.8$ Hz, COCH=), 6.25 (s, 2H, Ar-H), 7.13 (s,

2H, Ar-H), 7.36–7.41 (dd, 1H, J = 7.8, 12.2 Hz, =CHNH), 12.20 (d, 1H, J = 12.2 Hz, NH); MS found (M+H)⁺ (m/z): 404.20, Calcd for C₂₁H₂₅NO₇ m/z: 403.16.

(Z)-3-(1*H*-Indole-5-ylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10w)—

Starting from 1-(3,4,5-Trimethoxyphenyl)prop-2-yn-1-one **8c** and 5-aminoindole, 65% of **10w** was obtained as yellow solid according to above mentioned general procedure **10**. R_f = 0.24 (30% ethyl acetate in hexane). mp 174–175 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.98 (s, 3H, OCH₃), 4.01 (s, 6H, OCH₃), 6.01 (d, 1H, J = 7.6 Hz, COCH=), 6.60 (s, 1H, Ar-H), 7.07 (d, 1H, J = 6.7 Hz, Ar-H), 7.29–7.45 (m, 5H, Ar-H), 7.62–7.67 (dd, 1H, J = 7.6, 12.8 Hz, =CH-NH), 8.29 (bs, 1H, NH), 12.38 (d, 1H, J = 12.1 Hz, NH). MS found (M+H)⁺ (m/z): 353.20, Calcd for C₂₀H₂₀N₂O₄ m/z: 352.14.

(Z)-3-(1*H*-Indole-6-ylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10x)—

Starting from 1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8c** and 6-aminoindole, 69% of **10x** was obtained as yellow solid according to above mentioned general procedure **10**. R_f = 0.60 (30% ethyl acetate in hexane). mp 131–132 °C; ¹H NMR (CDCl₃, 300 MHz): δ 3.86 (s, 3H, OCH₃), 3.88 (s, 6H, OCH₃), 6.07 (d, 1H, J = 8.1 Hz COCH=), 7.16 (s, 2H, Ar-H), 7.19 (s, 1H, Ar-H), 7.48–7.60 (m, 1H, =CH-NH & 1H, Ar-H), 7.68–7.71 (m, 2H, Ar-H), 8.00 (d, 1H, J = 8.4 Hz, Ar-H), 8.72 (brs, 1H, NH), 12.26 (d, 1H, J = 12.3 Hz, NH). MS found (M+H)⁺ (m/z): 353.20, Calcd for C₂₀H₂₀N₂O₄ m/z: 352.14.

(Z)-3-(1*H*-Indole-7-ylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10y)—

Starting from 1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8c** and 7-aminoindole, 66% of **10y** was obtained as yellow solid according to above mentioned general procedure **10**. R_f = 0.82 (50% ethyl acetate in hexane). mp 86–87 °C; ¹H NMR (CDCl₃, 400 MHz): δ 3.86 (s, 3H, OCH₃), 3.87 (s, 6H, OCH₃), 6.01 (d, 1H, J = 7.4 Hz, COCH=), 6.55 (s, 1H, Ar-H), 6.96–7.09 (m, 3H, Ar-H), 7.15 (s, 2H, Ar-H), 7.40 (d, 1H, J = 7.6 Hz, Ar-H), 7.57–7.62 (dd, 1H, J = 7.8, 12.3 Hz, =CHNH), 8.75 (s, 1H, NH), 12.45 (d, 1H, J = 12.3 Hz, NH). MS found (M+H)⁺ (m/z): 353.30, Calcd for C₂₀H₂₀N₂O₄ m/z: 352.14.

(Z)-3-(1*H*-Indazole-5-ylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10z)

—Starting from 1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8c** and 4-aminoindazole, 65% of **10z** was obtained as yellow solid according to above mentioned general procedure **10**. R_f = 0.16 (50% ethyl acetate in hexane). mp 160–161 °C; ¹H NMR (CDCl₃, 300 MHz): δ 3.92 (s, 3H, OCH₃), 3.95 (s, 6H, OCH₃), 6.00 (d, 1H, J = 7.8 Hz, COCH=), 7.20 (s, 2H, Ar-H), 7.46–7.60 (m, 1H, =CH & 4H, Ar-H), 8.06 (s, 1H, NH), 12.31 (d, 1H, J = 12.3 Hz, NH). MS found (M+H)⁺ (m/z): 354.20, Calcd for C₁₉H₁₉N₃O₄ m/z: 353.14.

(Z)-3-(Quinolin-3-ylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10aa)—

Starting from 1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8c** and 3-aminoquinoline, 64% of **10aa** was obtained as yellow solid according to above mentioned general procedure **10**. R_f = 0.36 (50% ethyl acetate in hexane). mp 120–121 °C; ¹H NMR (CDCl₃, 300 MHz): δ 3.92 (s, 3H, OCH₃), 3.95 (s, 6H, OCH₃), 5.96 (d, 1H, J = 7.8 Hz, COCH=), 6.52–6.54 (m, 1H, Ar-H), 6.94–6.97 (m, 1H, Ar-H), 7.13 (brs, 1H, Ar-H), 7.17–7.19 (m, 1H, Ar-H), 7.22 (s, 2H, Ar-H), 7.55–7.62 (m, 1H, =CH-NH & 1H, Ar-H), 8.26 (brs, 1H, Ar-H), 12.35 (d, 1H, J = 12.3 Hz, NH). MS found (M+H)⁺ (m/z): 365.10, Calcd for C₂₁H₂₀N₂O₄ m/z: 364.14.

(Z)-3-(2-Methyl-1*H*-indole-5-ylamino)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (10ab)—

Starting from 1-(3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8c** and 5-amino-2-methylindole, 65% of **10ab** was obtained as yellow solid according to above mentioned general procedure **10**. R_f = 0.56 (50% ethyl acetate in hexane). mp 176–177 °C; ¹H NMR (CDCl₃, 400 MHz): δ 2.39 (s, 3H, CH₃), 3.85 (s, 3H, OCH₃), 3.88 (s, 6H, OCH₃), 5.86 (d,

1H, $J = 7.6$ Hz, COCH=), 6.13 (s, 1H, Ar-H), 6.83–6.85 (m, 1H, Ar-H), 7.16 (s, 2H, Ar-H), 7.17–7.20 (m, 2H, Ar-H), 7.48–7.53 (dd, 1H, $J = 7.6, 12.5$ Hz, =CH-NH), 7.87 (s, 1H, NH), 12.25 (d, 1H, $J = 12.3$ Hz, NH). MS found (M+H)⁺ (m/z): 367.20, Calcd for C₂₁H₂₂N₂O₄ m/z: 366.16.

(Z)-1-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(2-hydroxyphenylamino)prop-2-en-1-one (10ac)—Starting from 1-(2-bromo-3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8e** and 2-aminophenol, 70% of **10ac** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.66$ (50% ethyl acetate in hexane). mp 189–190 °C; ¹H NMR (CDCl₃, 300 MHz): δ 3.85 (s, 3H, OCH₃), 3.94 (s, 3H, OCH₃), 3.95 (s, 3H, OCH₃), 5.77 (d, 1H, $J = 7.5$ Hz, COCH=), 6.78–6.80 (m, 1H, Ar-H), 6.87–6.90 (m, 2H, Ar-H), 6.94 (s, 1H, Ar-H), 7.17–7.20 (m, 1H, Ar-H), 7.56–7.63 (dd, 1H, $J = 7.8, 13.2$ Hz, =CH-NH), 12.33 (d, 1H, $J = 13.2$ Hz, NH). MS found (M+H)⁺ (m/z): 408.10, Calcd for C₁₈H₁₈BrNO₅ m/z: 407.04.

(Z)-1-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(4-methoxyphenylamino)prop-2-en-1-one (10ad)—Starting from 1-(2-bromo-3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8e** and 4-methoxyphenylamine, 68% of **10ad** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.74$ (50% ethyl acetate in hexane). mp 70–71 °C; ¹H NMR (CDCl₃, 300 MHz): δ 3.81 (s, 3H, OCH₃), 3.88 (s, 3H, OCH₃), 3.91 (s, 3H, OCH₃), 3.92 (s, 3H, OCH₃), 5.63 (d, 1H, $J = 7.5$ Hz, COCH=), 6.86 (s, 1H, Ar-H), 6.89–6.93 (m, 2H, Ar-H), 7.05–7.09 (m, 2H, Ar-H), 7.37–7.44 (dd, 1H, $J = 7.5, 12.6$ Hz, =CH-NH), 11.94 (d, 1H, $J = 12.6$ Hz, NH). MS found (M+H)⁺ (m/z): 424.10, Calcd for C₁₉H₂₀BrNO₅ m/z: 421.05.

(Z)-1-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(3-hydroxy-4-methoxyphenylamino)prop-2-en-1-one (10ae)—Starting from 1-(2-bromo-3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8e** and 2-methoxy-5-aminophenol, 65% of **10ae** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.60$ (50% ethyl acetate in hexane). mp 150–151 °C; ¹H NMR (CDCl₃, 300 MHz): δ 3.81 (s, 3H, OCH₃), 3.89 (s, 3H, OCH₃), 3.91 (s, 3H, OCH₃), 3.92 (3H, OCH₃) 5.64 (d, 1H, $J = 7.5$ Hz, COCH=), 5.73 (brs, 1H, OH), 6.58–6.62 (m, 1H, Ar-H), 6.76–6.84 (m, 2H, Ar-H), 6.86 (s, 1H, Ar-H), 7.34–7.41 (dd, 1H, $J = 7.5, 12.6$ Hz, =CH-NH), 11.86 (d, 1H, $J = 12.3$ Hz, NH). MS found (M+H)⁺ (m/z): 438.10, Calcd for C₁₉H₂₀BrNO₆ m/z: 437.05.

(Z)-1-(2-Bromo-3,4,5-trimethoxyphenyl)-3-(1H-indol-5-ylamino)prop-2-en-1-one (10af)—Starting from 1-(2-bromo-3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8e** and 5-aminoindole, 64% of **10af** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.70$ (50% ethyl acetate in hexane). mp 109–110 °C; ¹H NMR (CDCl₃, 300 MHz): δ 3.78 (s, 3H, OCH₃), 3.83 (s, 6H, OCH₃), 5.54 (d, 1H, $J = 7.5$ Hz, COCH=), 6.42 (s, 1H, Ar-H), 6.80 (s, 1H, Ar-H), 6.87–7.91 (m, 1H, Ar-H), 7.13–7.18 (m, 1H, Ar-H), 7.25–7.30 (m, 2H, Ar-H), 7.42–7.49 (dd, 1H, $J = 7.6, 12.7$ Hz, =CH-NH), 8.50 (s, 1H, NH), 12.00 (d, 1H, $J = 12.6$ Hz, NH). MS found (M+H)⁺ (m/z): 431.10, Calcd for C₂₀H₁₉BrN₂O₄ m/z: 430.05.

(Z)-1-(2-Chloro-3,4,5-trimethoxyphenyl)-3-(3-hydroxy-4-methoxyphenylamino)prop-2-en-1-one (10ag)—Starting from 1-(2-chloro-3,4,5-trimethoxyphenyl)prop-2-yn-1-one **8d** and 2-methoxy-5-aminophenol, 65% of **10ag** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.60$ (50% ethyl acetate in hexane). mp 102–103 °C; ¹H NMR (CDCl₃, 300 MHz): δ 3.89 (s, 3H, OCH₃), 3.90 (s, 3H, OCH₃), 3.93 (s, 3H, OCH₃), 3.94 (3H, OCH₃) 5.73 (d, 1H, $J = 7.5$ Hz, COCH=), 5.76 (brs, 1H, OH), 6.59–6.63 (m, 1H, Ar-H), 6.76–6.85 (m, 2H, Ar-H), 6.86 (s,

1H, Ar-H), 7.35–7.42 (dd, 1H, $J = 7.5, 12.6$ Hz, =CH-NH), 11.93 (d, 1H, $J = 12.3$ Hz, NH). MS found (M+H)⁺ (m/z): 394.20, Calcd for C₁₉H₂₀ClNO₆ m/z: 393.10.

(Z)-3-(4-Methoxyphenylamino)-1-(3,4,5-trimethoxy-2-nitrophenyl)prop-2-en-1-one (10ah)—Starting from 1-(3,4,5-Trimethoxy-2-nitrophenyl)prop-2-yn-1-one **8f** and 4-methoxyphenylamine, 60% of **10ah** was obtained as yellow solid according to above mentioned general procedure **10**. $R_f = 0.68$ (50% ethyl acetate in hexane). mp 132–133 °C; ¹H NMR (CDCl₃, 300 MHz): δ 3.82 (s, 3H, OCH₃), 3.96 (s, 6H, OCH₃), 4.00 (s, H, OCH₃), 5.63 (d, 1H, $J = 7.5$ Hz, COCH=), 6.89–6.92 (m, 2H, Ar-H), 6.97 (s, 1H, Ar-H), 7.04–7.07 (m, 2H, Ar-H), 7.39–7.45 (dd, 1H, $J = 7.5, 12.6$ Hz, =CH-NH), 11.93 (d, 1H, $J = 12.9$ Hz, NH). MS found (M+H)⁺ (m/z): 389.10, Calcd for C₁₉H₂₀N₂O₇ m/z: 388.13.

Biology

Tissue Culture and Reagents—Paclitaxel was purchased from Sigma. Cell lines were purchased from ATCC. Cell lines were routinely grown in DMEM or RPM1 (CellGro) supplemented with 10% fetal bovine serum (CellGeneration, CO) and 1 unit/mL penicillinstreptomycin (Gibco).

Cytotoxicity Assay—We have tested a number of tumor cell lines using a dose response end point assay system. The cells were grown in either DMEM or RPMI supplemented with 10% fetal bovine serum and 1 unit/mL Penicillin-Streptomycin solution. The tumor cells were plated into 6 well dishes at a cell density of 1.0×10^5 cells/mL/well and compounds were added 24 h later at various concentrations. Cell counts were determined from duplicate wells after 96 h of treatment. The total number of viable cells was determined by trypan blue exclusion.

Flow Cytometry—Cancer cell line DU145 (human prostate tumor) cells, were grown in DMEM (Cellgro) supplemented with 10% fetal bovine serum and 1 unit/mL penicillinstreptomycin. The cells were plated onto 100 mm² dishes at a cell density of 1.0×10^6 cells/dish, and 24 h later, they were treated with 2.5 μ M of the compound. The cells were harvested 24, 48 and 72 h after treatment. The cells were removed from the plate by trypsin digestion and combined with the non-attached cells found in the medium. The cell pellets were washed in phosphate buffered saline (PBS), and fixed in ice cold 70% ethanol for at least 24 h. The fixed cells were then washed with room temperature PBS and stained with propidium iodide (50 mg/mL) and RNase A (0.5 mg) for 30 min at 37 °C. The stained cells were then analyzed on a Becton-Dickinson (BD) (FACScan) flow cytometer and the data analyzed by cell cycle analysis software (Modfit, BD).

Western Blotting Analysis—Hela cells were harvested at the indicated times and cell pellets were frozen on dry ice before lysis. Cell pellets were lysed (25 mM HEPES, 0.1% Triton-X100, 300 mM NaCl, 20 mM β -glycerophosphate, 0.5 mM DTT, 1.0 mM EDTA, 1.5 mM MgCl₂, pH 7.5, 0.2 mM sodium orthovanadate, and protease inhibitors). 100 μ g of each lysate was resolved by 10%-SDS-polyacrylamide gel electrophoresis. The resolved proteins were transferred onto nitrocellulose filter paper and hybridized to the following antibodies: phosphospecific histone H3 (Upstate;cat#05-806), histone H3 (upstate;cat#07-690), bcl-2 (BD Biosciences;cat#610558), bub R1 (BD Biosciences;cat#612503), plk-1(Santa Cruz; sc-17783), cyclin B1(Santa Cruz;sc- 594), PARP (BD Biosciences;cat#556362 and GAPDH (Fitzgerald;cat#RDI-TRK5G4-6C5). Following the primary hybridization, the blots were then treated with secondary antibodies conjugated to infrared dyes (IRDye 800 or IRDye 680) and analyzed on an infrared scanning system (Odyssey, Li-Cor Biosciences, NE). All hybridization and washing conditions were performed as specified by the manufacturer. Quantitation of the bands was performed using Odyssey software. Fold increase was

determined by first normalizing each band against GAPDH and then dividing that number by the value of the normalized control.

PARP Western—DU145 cells were plated at a density of 3.0×10^6 cells per 150 mm² plate and treated 24 h later with either DMSO or **10ae**. The cells were collected at the indicated time points and cell pellets were frozen. The frozen cell pellets were lysed in 1% NP40/PBS lysis buffer containing protease inhibitors. Equal amounts of total cellular protein was then resolved on a 10%-SDS-polyacrylamide gel. The gels were transferred onto nitrocellulose paper (S/S), hybridized with anti-PARP antibodies (BD) and developed using ECL (Perkin-Elmer, MA) solution.

Tubulin Polymerization—MAP-rich tubulin from bovine brain (Cytoskeleton), resuspended in PEM [80 mM PIPES, (pH 6.9), 0.5 mM EGTA, 2 mM MgCl₂], was pre-incubated with drug or its vehicle dimethyl sulfoxide at room temperature for 5 min. PEG containing GTP was added to start the tubulin polymerization reaction. The reaction was monitored by a spectrophotometer at OD350nm at 37 °C. The final concentrations of tubulin and GTP were 1.15 mg/mL and 4 mM, respectively.

Tubulin Staining—Hela cells were grown on glass coverslips and treated with **10ae** (0.25 μM, 0.5 uM), paclitaxel (0.005 μM) or vincristine (0.005 μM) for 18 h. The coverslips were washed in phosphate buffered saline and fixed in freshly prepared 4% paraformaldehyde. The cells were blocked and permeabilized and stained with 1:400 dilution of anti-α-tubulin conjugated with FITC (Sigma) followed by staining with DAPI (0.5 ug/mL). The coverslips were mounted onto glass slides using Prolong Gold Antifade, (Molecular Probes/Invitrogen, CA) solution and visualized using an Olympus IX-71 inverted fluorescent microscope at 100x magnification. The cells were photographed using the DP-71 camera system using two filters followed by merging and representative merged images are shown.

Acknowledgments

This work was supported by grants from the NIH (CA 109820) and Onconova Therapeutics Inc.

ABBREVIATIONS USED

MSA	microtubule-stabilizing agents
GTP	guanosine triphosphate
FACs	fluorescence-activated cell sorting
PLK-1	Polo-like kinase-1
Bcl-2	B-cell lymphoma-2
MAPS	microtubule-associated proteins
GAPDH	Glyceraldehyde 3-phosphate dehydrogenase
PARP	Poly(ADP-ribose)polymerase

References

1. Downing KH, Nogales E. Tubulin and microtubule structure. *Curr Opin Cell Biol.* 1998; 10:16–22. [PubMed: 9484591]
2. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. *Med Res Rev.* 1998; 18:259–296. [PubMed: 9664292]

3. Hamel E. Antimitotic natural products and their interactions with tubulin. *Med Res Rev.* 1996; 16:207–231. [PubMed: 8656780]
4. (a) Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FALM, Horsman MR, Marme D, LoRusso PM. Differentiation and definition of vascular targeted-therapies. *Clin Cancer Res.* 2005; 11:416–420. [PubMed: 15701823] (b) Siemann, DW. *Vascular- Targeted Therapies in Oncology.* John Wiley & Sons; New York: 2006. (c) Gaya AM, Rustin GJ. Vascular disrupting agents: A new class of drug in cancer therapy. *Clin Oncol.* 2005; 17:277–290. (d) Tozer GM, Kanthou C, Baguley BC. Disrupting tumor blood vessels. *Nat Rev Cancer.* 2005; 5:423–435. [PubMed: 15928673] (e) Lippert JW III. Vascular disrupting agents. *Bioorg Med Chem.* 2007; 15:605–615. [PubMed: 17070061]
5. (a) Chaplin DJ, Horsman MR, Siemann DW. Current developments status of small-molecule vascular disrupting agents. *Curr Opin Invest Drugs.* 2006; 7:522–528. (b) Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA. Medicinal chemistry of combretastatin A4: present and future directions. *J Med Chem.* 2006; 49:3033–3044. [PubMed: 16722619] (c) Li Q, Sham HL. Discovery and development of mitotic agents that inhibit polymerization for the treatment of cancers. *Expert Opin Ther Pat.* 2002; 12:1663–1702. (d) Nam NH. Combretastatin A4 analogues as antimitotic antitumor agents. *Curr Med Chem.* 2003; 10:1697–1722. [PubMed: 12871118] (e) Hsieh HP, Liou JP, Mahindroo N. Pharmaceutical design of antimitotic agents based on combretastatin. *Curr Pharm Des.* 2005; 11:1655–1677. [PubMed: 15892667] (f) Mahindroo N, Liou JP, Chang JY, Hsieh HP. Antitubulin agents for the treatment of cancer- a medicinal chemistry updates. *Expert Opin Ther Pat.* 2006; 16:647–691. (g) Tron GC, Pagliai F, Del Grosso E, Genazzani AA, Sorba G. Synthesis and cytotoxic evaluation of combretafurazans. *J Med Chem.* 2005; 48:3260–3268. [PubMed: 15857132] (h) Pirali T, Busacca S, Beltrami L, Imovilli D, Pagliai F, Miglio G, Massarotti A, Verotta L, Tron GC, Sorba G, Genazzani AA. Synthesis and cytotoxicity evaluation of combretafuran, potential scaffolds for dual-action antitumor agents. *J Med Chem.* 2006; 49:5372–5376. [PubMed: 16913727] (i) Zhang Q, Peng Y, Wang XI, Keenan SM, Arora S, Welsh WJ. Highly potent triazole-based tubulin polymerization inhibitors. *J Med Chem.* 2007; 50:749–754. [PubMed: 17249649]
6. Pinney KG, Bounds AD, Dingeman KM, Mocharla VP, Pettit GR, Bai R, Hamel E. A new anti-tubulin agent containing the benzo[b]thiophene ring system. *Bioorg Med Chem Lett.* 1999; 9:1081–1086. [PubMed: 10328289]
7. Flynn BL, Hamel E, Jung MK. One pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. *J Med Chem.* 2002; 45:2670–2673. [PubMed: 12036378]
8. Wang L, Woods KW, Li Q, Barr KJ, McCroskey RW, Hannick SM, Gherke L, Credo RB, Hui YH, Marsh K, Warner R, Lee JY, Zielinski-Mozng N, Frost D, Rosenberg SH, Sham HL. Potent, oral active heterocyclebased combretastatin C-4 analogues: synthesis, structure activity- relationship, pharmacokinetics, and *in vivo* antitumor activity evaluation. *J Med Chem.* 2002; 45:1697–1711. [PubMed: 11931625]
9. Niher Y, Suga Y, Morinaga Y, Akiyama Y, Tsuji T. Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. *Bioorg Med Chem Lett.* 1998; 8:3153–3158. [PubMed: 9873694]
10. Szczepankiewicz BG, Liu G, Jae HS, Tasker AS, Gunawardana IW, von Geldern TW, Gwaltney SL II, Wu-Wong JR, Gehrke L, Chiou WJ, Credo RB, Alder JD, Nukkala MA, Zielinski NA, Jarvis K, Mollison KW, Frost DJ, Bauch JL, Hui YH, Claiborne AK, Li Q, Rosenberg SH. New mitotic agents with activity in multidrug-resistant cell lines and *in vivo* efficacy in murine tumor models. *J Med Chem.* 2001; 44:4416–4430. [PubMed: 11728187]
11. Mahboobi S, Pongratz H, Hufsky H, Hockemeyer J, Frieser M, Lyssenko A, Paper DH, Burgermeister J, Bohmer FD, Fiebig HH, Burger AM, Baasner S, Beckers T. Synthetic 2-aryolindole derivatives as new class of potent inhibitory, antimitotic agents. *J Med Chem.* 2001; 44:4535–4553. [PubMed: 11741473]
12. (a) Liou JP, Chang YL, Kuo FM, Chang CW, Tseng HY, Wang CC, Yang YN, Chang JY, Lee SJ, Hsieh HP. Concise synthesis and structure- activity relationships of combretastatin A-4 analogues, 1-aryolindoles, 3-aryolindoles, a novel classes of potent antitubulin agent. *J Med Chem.* 2004; 47:4247–4257. [PubMed: 15293996] (b) Liou JP, Mahindroo N, Chang CW, Guo FM, Lee SWH, Tan UK, Yeh TK, Kuo CC, Chang YW, Lu PH, Tung YS, Lin KT, Chang JY,

- Hsieh HP. Structure-activity relationship studies of 3-aryloindole as potent antitumorigenic agents. *Chem Med Chem*. 2006; 1:1106–1118. [PubMed: 16952120]
13. Martino GD, Edler MC, Regina GL, Coluccia A, Barbera MC, Barrow D, Nicholson RI, Chiosis G, Brancale A, Hamel E, Artico M, Silvestri R. New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. *J Med Chem*. 2006; 49:947–954. [PubMed: 16451061]
 14. Bacher G, Nickel B, Emig P, Vanhoefer U, Seeber S, Shandra A, Klenner T, Beckers T. D-24851, a novel synthetic microtubule inhibitor, expressive curative antitumoral activity *in vivo*, shows efficacy toward multidrug-resistant tumor cells and lacks neurotoxicity. *Cancer Res*. 2001; 61:392–399. [PubMed: 11196193]
 15. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, Chang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. *Leukemia*. 1993; 7:563–568. [PubMed: 8096557]
 16. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. *Curr Med Chem Anti-Canc Agents*. 2002; 2:1–17.
 17. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly *in vitro* by taxol. *Nature*. 1979; 277:665–667. [PubMed: 423966]
 18. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. *Proc Natl Acad Sci USA*. 1980; 77:1561–1565. [PubMed: 6103535]
 19. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM. Epothilones a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. *Cancer Res*. 1995; 55:2325–2333. [PubMed: 7757983]
 20. Ter Haar E, Kowalski RJ, Hamel E, Lin CM, Longely RE, Gunasekara SP, Rosenkranz HS, Day DW. Discodermolide a cytotoxic marine agent that stabilizes microtubules more potently than taxol. *Biochemistry*. 1996; 35:243–250. [PubMed: 8555181]
 21. Stephen JH, Thomas UM, David TM, Rejza F, Randall WK, Timothy JM, Stuart LS. Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis. *Chem Biol*. 2000; 7:275–286. [PubMed: 10780927]
 22. Yasushi S, Toshimasa T, Yukimasa N. GS-164, a small synthetic compound, stimulates tubulin polymerization by a similar mechanism to that of Taxol. *Cancer Chemother Pharmacol*. 1997; 40:513–520. [PubMed: 9332466]
 23. Molander GA, George KM, Monovich LG. Total synthesis of (+)-Isoschizaandrin utilizing a samarium (II) iodide-promoted 8-endo ketyl-olefin cyclization. *J Org Chem*. 2003; 68:9533–9540. [PubMed: 14656077]
 24. Harker WG, Sikic BI. Multidrug (pleiotropic) resistance in doxorubicin selected variants of the human sarcoma cell lines MES-SA. *Cancer Res*. 1985; 45:4091–4096. [PubMed: 4028002]
 25. Patricia K, Andrew EP, Tao L, Buzz B. Moesin controls cortical rigidity cell rounding spindle morphogenesis during mitosis. *Current Biol*. 2008; 18:91–101.
 26. Lanzi C, Cassinelli G, Cuccuru G, Supino R, Zuco V, Ferlini C, Scambia G, Zunino F. Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. *Prostate*. 2001; 48:254–264. [PubMed: 11536305]
 27. Nawab A, Thakur VS, Yunus M, Ali MA, Gupta S. Selective cell cycle arrest and induction of apoptosis in human prostate cancer cells in polyphenol – rich extract in solanum ingrum. *Int J Mol Med*. 2001; 29:277–284. [PubMed: 22076244]
 28. Jeffrey HW, Zhaozong Z, Jun G, Ann RK, Levy K. Establishment of human cancer cell clones with different characteristics: A model for screening chemopreventive agents. *Anticancer Research*. 2007; 27:1–16. [PubMed: 17352209]
 29. Kiranmai G, Ramana Reddy MV, Stephen CC, Boominathan R, Stacy JB, Nabisa P, Jiandong J, James H, Premkumar EP. ON1910, a non-ATP competitive small molecule inhibitor of PLK1, is a potent cancer agent. *Cancer Cell*. 2005; 7:275–286. [PubMed: 15766665]
 30. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, Bazett-Jones DP, Allis CD. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. *Chromosoma*. 1997; 10:348–360. [PubMed: 9362543]

31. Van Hooser A, Goodrich DW, Allis CD, Brinkley BR, Mancini MA. HistoneH3 phosphorylation is required for the initiation, but not maintenance, of mammalian chromosome condensation. *J Cell Sci.* 1998; 111:3497–3506. [PubMed: 9811564]
32. Prigent C, Dimitrov S. Phosphorylation of serine 10 in histone H3, what for? *J Cell Sci.* 2003; 116:3677–3685. [PubMed: 12917355]
33. Coleman KE, Brat DJ, Cotsonis GA, Lawson D, Cohen C. Proliferation (MIB-1 expression) in oligodendrogliomas: assessment of quantitative methods and prognostic significance. *Appl Immunohistochem Mol Morphol.* 2006; 14:109–114. [PubMed: 16540741]
34. Ling YH, Tornos C, Perez-Soler R. Phosphorylation of Bcl-2 is a marker of M phase events not a determinant of apoptosis. *J Biol Chem.* 1998; 273:18984–18991. [PubMed: 9668078]
35. Nurse P. Universal control mechanism regulating onset of M-phase. *Nature.* 1990; 344:503–508. [PubMed: 2138713]
36. King RW, Jackson PK, Kirschner MW. Mitosis in transition. *Cell.* 1994; 79:563–571. [PubMed: 7954823]
37. Golesteyn RM, Schultz SJ, Bartek J, Ziemiecki A, Ried T, Nigg EA. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases *drosophila* polo and *saccharomyces cerevisiae* Cdc5. *J Cell Sci.* 1994; 107:1509–1517. [PubMed: 7962193]
38. Chan GK, Jablonski SA, Sudakin V, Hittle JC, Yen TJ. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. *J Cell Biol.* 1999; 146:941–954. [PubMed: 10477750]
39. Birk M, Burkle A, Pekari K, Maier T, Schmidt M. Cell cycle dependent cytotoxicity and mitotic spindle checkpoint dependency of investigational and approved anti-mitotic agents. *Int J Cancer.* 2011 (In press).
40. Soldani C, Scovassi AI. Poly (ADP-ribose) polymerase-1 cleavage during apoptosis: an update. *Apoptosis.* 2002; 7:321–328. [PubMed: 12101391]

Figure 1.

10ae treatment of cancer cells results in G2/M arrest. DU145, human prostate cancer cells were treated for 24 h with increasing concentrations of **10ae**, fixed and stained with propidium iodide and analyzed for their DNA content by flow cytometry. G1 (2N) S-Phase (>2N<4N) and G2/M (4N) cells are indicated solid blue, striped, and solid red, respectively. **10ae** treated cells become arrested in G2/M in a dose responsive manner. DU145 cells were plated at a cell density of 1.0×10^6 cells per 100mm dish. N=3

Figure 2.

10ae treatment induces mitotic arrest. HeLa cells were treated with 1 μ M **10ae** and cells were harvested for western blotting at the indicated times. The blot was sequentially hybridized with antibodies specific for phospho-histone H3, histone H3, cyclin B1, PLK-1, BubR1 and GAPDH was used as a loading control. Phosphorylation of histone H3, BubR1 and Bcl-2 and the accumulation of mitotic specific proteins (cyclin B1 and PLK-1) indicates that **10ae** treatment induces a mitotic arrest with cells starting to accumulate in mitosis by 6 h following treatment. Primary antibody dilutions were 1:1000 for all westerns, and 1:10,000 for secondary antibodies. N=3. The numbers below the panel represents the fold increase,

calculated as described in materials and methods, of the respective protein, or phospho-protein.

Figure 3.

10ae treatment activates caspase-3 and induces apoptosis. HeLa cells were treated with 1.0 μ M **10ae** for the indicated times and protein lysates were resolved by SDS-PAGE and analyzed for caspase-3 activation by western blotting using anti-PARP specific antibodies. PARP cleavage was observed starting at 24 h. This data indicates that the apoptosis pathway has been activated. Primary antibody dilutions were 1:1000 for all westerns, and 1:10,000 for secondary antibodies. N=3

Figure 4.

MAP-rich tubulin from bovine brain had been pre-incubated with various drugs (1 μ M final) or vehicle dimethyl sulfoxide at room temperature for 5 min before guanosine triphosphate (GTP) was added to start the tubulin polymerization reactions. The reaction was monitored at various time points at OD350nm at 37 °C. Tubulin polymerization enhancer (Taxol) and inhibitor (Vincristine) were included as controls.

Figure 5.

10ae treatment results in abnormal microtubule spindle development. HeLa cells were treated with 0.25 μM or 0.5 μM of **10ae**, 0.005 μM paclitaxel, 0.005 μM vincristine or DMSO for 18 h and fixed and stained with anti-α-tubulin-FITC specific antibodies (green) followed by DAPI to visualize chromosomes (blue). **10ae** and paclitaxel treatment resulted in abnormal mitotic cells with chromosomes not aligned at the metaphase plate (see arrows) without complete loss of tubulin polymers as observed in cells treated with vincristine. Cell density was 1.0×10^6 cells per 100mm dish containing 8 coverslips each.

Figure 6. **10ae** treatment does not alter cytoplasmic microtubules. High concentrations of **10ae** (0.5 μM) did not result in bundling of the cytoplasmic microtubules near as seen with paclitaxel (0.005 μM) treatment (arrow) nor did **10ae** treatment depolymerize cytoplasmic microtubules as observed in cells treated with vincristine (0.005 μM). Cell density was 1.0×10^6 cells per 100mm dish containing 8 coverslips each.

Scheme 1.

Synthesis of (*Z*)- 1-Aryl-3-aryl-amino-2-propen-1-one from 1-aryl-2-propyn-1-one^a

^aReagents and conditions: (a) Ethynylmagnesium bromide, THF, 0 °C-rt, 8–9 h, 60–70 %;

(b) 2-iodoxybenzoic acid, DMSO, rt, 5 h, 70–72 %; (c) ethanol, rt, 4 h, 60–82 %. H₂N Y Y

= Aryl or Heteroaryl

Scheme 2. Synthesis of 2-Chloro-3,4,5-trimethoxybenzaldehyde^a^aReagents and Conditions: (a) Sulfuryl chloride, dichloromethane, rt, 2 h, 60 %.

Scheme 3. Synthesis of 2-Bromo-3,4,5-trimethoxybenzaldehyde^a^aReagents and conditions: (a) NBS, chloroform, reflux, 3 h, 97 %.

Scheme 4. Synthesis of 2-Nitro-3,4,5-trimethoxybenzaldehyde^a^aReagents and Conditions: (a) Anhydrous toluene, diisobutylaluminum hydride, -50°C , 30 min, 55 %; (b) chloroform, manganese dioxide, rt, 48 h, 63 %.

Chart 1.
Examples of Tubulin Interacting Agents

Table 1

In vitro cytotoxicity of (Z)-1-Aryl-3-arylamino-2-propen-1-one **10**

Comp.	X	Y	IC ₅₀ (μM)	
			DU145	K562
10a	4-OCH ₃	4-OCH ₃ -C ₆ H ₄	75	100
10b	4-OCH ₃	3,4,5-(OCH ₃) ₃ -C ₆ H ₂	50	75
10c	2,4,6-(OCH ₃) ₃	4-OCH ₃ -C ₆ H ₄	75	75
10d	2,4,6-(OCH ₃) ₃	2-OH-C ₆ H ₄	25	75
10e	2,4,6-(OCH ₃) ₃	4-Cl-C ₆ H ₄	25	25
10f	2,4,6-(OCH ₃) ₃	2,4-(OCH ₃) ₂ -C ₆ H ₃	75	75
10g	2,4,6-(OCH ₃) ₃	2,4,6-(OCH ₃) ₃ -C ₆ H ₂	75	50
10h	2,4,6-(OCH ₃) ₃	3,4,5-(OCH ₃) ₃ -C ₆ H ₂	35	75
10i	3,4,5-(OCH ₃) ₃	2-OH-C ₆ H ₄	0.25	0.5
10j	3,4,5-(OCH ₃) ₃	3-OH-C ₆ H ₄	0.75	0.5
10k	3,4,5-(OCH ₃) ₃	2-OCH ₃ -C ₆ H ₄	2.5	2.5
10l	3,4,5-(OCH ₃) ₃	4-OCH ₃ -C ₆ H ₄	0.5	0.5
10m	3,4,5-(OCH ₃) ₃	4-Cl-C ₆ H ₄	0.5	0.25
10n	3,4,5-(OCH ₃) ₃	4-OCF ₃ -C ₆ H ₄	3	20
10o	3,4,5-(OCH ₃) ₃	4-CF ₃ -C ₆ H ₄	0.5	0.5
10p	3,4,5-(OCH ₃) ₃	3-OH,4-OCH ₃ -C ₆ H ₃	0.1	0.1
10q	3,4,5-(OCH ₃) ₃	3-NH ₂ ,4-OCH ₃ -C ₆ H ₃	0.1	0.25
10r	3,4,5-(OCH ₃) ₃	3-F,4-OCH ₃ -C ₆ H ₃	0.25	0.25
10s	3,4,5-(OCH ₃) ₃	3-Cl,4-OCH ₃ -C ₆ H ₃	0.2	0.25
10t	3,4,5-(OCH ₃) ₃	2-Cl,5-OH-C ₆ H ₃	0.75	2.5
10u	3,4,5-(OCH ₃) ₃	2,4,6-(OCH ₃) ₃ -C ₆ H ₂	75	50
10v	3,4,5-(OCH ₃) ₃	3,4,5-(OCH ₃) ₃ -C ₆ H ₂	40	25
10w	3,4,5-(OCH ₃) ₃	5-Indolyl	0.2	0.5
10x	3,4,5-(OCH ₃) ₃	6-Indolyl	0.1	0.2
10y	3,4,5-(OCH ₃) ₃	7-Indolyl	2.5	2.5
10z	3,4,5-(OCH ₃) ₃	4-Indazole	0.75	2.5
10aa	3,4,5-(OCH ₃) ₃	3-Quinoline	0.5	0.75
10ab	3,4,5-(OCH ₃) ₃	2-CH ₃ ,5-Indolyl	0.6	0.75

Comp.	X	Y	IC ₅₀ (μM)	
			DU145	K562
10ac	2-Br,3,4,5-(OCH ₃) ₃	2-OH- C ₆ H ₄	0.25	0.2
10ad	2-Br,3,4,5-(OCH ₃) ₃	4-OCH ₃ -C ₆ H ₄	0.2	0.25
10ae	2-Br,3,4,5-(OCH ₃) ₃	3-OH,4-OCH ₃ -C ₆ H ₃	0.06	0.1
10af	2-Br,3,4,5-(OCH ₃) ₃	5-Indolyl	0.15	0.2
10ag	2-Cl,3,4,5-(OCH ₃) ₃	3-OH,4-OCH ₃ -C ₆ H ₃	0.2	0.25
10ah	2-NO ₂ ,3,4,5-(OCH ₃) ₃	4-OCH ₃ -C ₆ H ₄	0.6	0.6

Standard Deviation for IC₅₀ values were all within +/- 0.05 μM

Table 2Evaluation of **10ae** against a panel of Human Tumor Cell lines

Cell Line	Tumor Type	10ae (μM)
BT20	Breast (ER-)	0.75
MCF-7	Breast (ER+)	0.4
SK-BR-3	Breast (ER-)	0.3
BT474	Breast (ER+)	0.1
DU145	Prostate (AR-)	0.06
MIA-Paca2	Pancreatic	0.8
A549	NSCLC	0.9
Hela	Cervical	0.2
COLO-320	Colo-rectal	0.15
Panc-1	Pancreatic	0.2
K562	CML	0.1
SK-MEL-28	Melanoma	0.2
HTB-126	Breast Carcinoma	0.1
Caco-2	Colo-rectal	0.25
Raji	Burkitt's Lymphoma (B-cell)	0.2
SNU-5	Gastric Carcinoma	0.25
N87	Gastric Carcinoma	0.3
HCT-15	Colo-rectal	0.04
MES-SA	Sarcoma	0.25
MES-SA/DX5	Resistant Sarcoma	0.50

Standard Deviation for IC50 values were all within $\pm 0.025 \mu\text{M}$